CSF2 and Crohn disease: Recombinant human GM-CSF administration was reported to decrease Crohn’s disease severity and improve quality of life [93], allow for increased chemotherapy dosing by serving as a GI mucosal protectant [94], improve GI permeability in chemotherapy-induced stomatitis [95], and increase monocyte-induced cytotoxicity of colon adenocarcinoma [96].